Strategic partnerships ITM's global radiopharmaceutical production capability and recent partnership with Akiram Therapeutics indicate a readiness to collaborate with mid-to-large biotech developers on clinical programs leveraging Lu-177 based therapies, presenting a sales opportunity for contract manufacturing, supply agreements, and co-development arrangements.

Expansion and capacity The 7,000 square meter facility expansion in Germany to boost Lutetium-177 production tenfold signals enhanced capacity and regional supply resilience, enabling BD outreach to oncology customers seeking reliable, scalable radiopharmaceutical manufacturing and logistics in Europe.

Phase 3 readiness ITM maintains a robust precision oncology pipeline with multiple Phase 3 studies and compelling trial readouts on ITM-11, creating near-term sales potential for turnkey radiopharma production, regulatory support, and early-access supply agreements for late-stage products.

Clinical outcomes focus Positive trial endpoints and quality-of-life data presentations at ASCO, ENETS, and ESMO underscore ITM’s value proposition to payers and clinicians, offering an entry point for partnerships around outcomes-based supply contracts and real-world data collaboration.

Global supply network With two decades of radiopharma expertise and an established global network, ITM is positioned to serve multinational oncology programs, providing opportunities for strategic sourcing, cross-border distribution arrangements, and integrated radiopharmacy services across regions.